BRAF and colorectal carcinoma: Corcoran et al. reported that EGFR levels were elevated before and after treatment with vemurafenib (BRAF inhibitor), suggesting that EGFR is overactivated in BRAF-mutant CRC cells regardless of BRAF inhibition.